Key result
An individualized low-molecular-weight heparin bridging protocol for outpatients on oral anticoagulants undergoing invasive procedures resulted in a 0.4% rate of thromboembolic events.
Why the study?
Does an individualized low-molecular-weight heparin bridging protocol prevent thromboembolic events without excessive bleeding in outpatients on oral anticoagulants undergoing invasive procedures?
Population
1,262 outpatients on oral anticoagulants undergoing invasive procedure or surgery
Design
Cohort
Follow-up
30 days
Authors
Loading...
Individualized LMWH bridging shows low TE and bleeding rates in outpatients; leaves open definitive safety for mechanical valves without randomized confirmation.
Cohort (n=1,262)
Does an individualized low-molecular-weight heparin bridging protocol prevent thromboembolic events without excessive bleeding in outpatients on oral anticoagulants undergoing invasive procedures?
A risk-tailored LMWH bridging protocol for outpatients on oral anticoagulants is feasible and associated with low rates of thromboembolism, though major bleeding risk is increased with therapeutic-dose bridging.
Pengo et al. (2009) conducted a cohort in Outpatients on oral anticoagulants undergoing invasive procedure or surgery (n=1,262). Individualized low-molecular-weight heparin bridging protocol was evaluated on Thromboembolic events (95% CI 0.1 to 0.9). An individualized low-molecular-weight heparin bridging protocol for outpatients on oral anticoagulants undergoing invasive procedures resulted in a 0.4% rate of thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: